Changes in Expression of miR-128, miR-144-3p, miR-181b, and miR-451 in Response to Treatment of Pediatric Acute Lymphoblastic Leukemia (B-ALL)

Document Type : Original Article(s)

Authors

1 Department of Hematology, Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

2 Assistant Professor, Department of Clinical Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran

3 Department of Biotechnology, Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

4 Associate Professor, Department of Pediatrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

5 PhD of Veterinary Medicine, Research Center for Noncommunicable Diseases, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran

6 PhD of Veterinary Medicine, Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran

7 Assistant Professor, Research Center for Noncommunicable Diseases, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran

8 Assistant Professor, Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Acute lymphoblastic leukemia (ALL) is the most common leukemia in children. Changes in the expression of microRNAs occur in ALL. The purpose of this study was to investigate the importance of miR-128, miR-144-3p, miR-181b, and miR-451 in diagnosis and response to treatment in children with B-ALL.Methods: In this study, serum samples were collected from 12 children with B-ALL at diagnosis, as well as 12 healthy individuals as a control group. All patients received chemotherapy and after treatment entered in this study, and the expression of miR-128, miR-144-3p, miR-181b, and miR-451 was evaluated after and before treatment of patients.Finding: miR-144 was significantly downregulated in newly diagnosed patients with ALL compared to control groups (0.26 fold, P = 0.020), and also the expression of miR-144-3P significantly increased after treatment in comparison to before it (4 fold, P < 0.001). In addition, miR-128 (0.11, P = 0.006), and mir-181b (0.34 fold, P = 0.040) expression significantly decreased after treatment compared to newly diagnosed patients.Conclusion: The reduced expression of miR-144-3p can be served as diagnostic biomarker, and upregulation of miR-144-3p can predict treatment response in patients with ALL. Moreover, the abnormally reduced expression of miR-128 and miR-181b after the treatment of patients, indicate that these microRNAs can be candidate as therapeutic biomarker in pediatric ALL.

References

  1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381(9881): 1943-55.
  2. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer J 2017; 7(6): e577.
  3. Rahmani F, Abdi N, Zaj P, Rostaminezhad A, Behnammoghadam M, Rahmani F. Management and treatment in acute lymphoblastic leukemia: A review article. Adv Environ Biol 2014; 8(10): 1642-7.
  4. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29(5): 532-43.
  5. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 2018; 9: 402.
  6. Farzadfard E, Kalantari T, Tamaddon G. Serum expression of seven microRNAs in chronic lymphocytic leukemia patients. J Blood Med 2020; 11: 97-102.
  7. Gutierrez-Camino A, Garcia-Obregon S, Lopez-Lopez E, Astigarraga I, Garcia-Orad A. miRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review. Epigenomics 2020; 12(1): 69-80.
  8. Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci 2016; 17(10): 1712.
  9. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, function and role in cancer. Curr Genomics 2010; 11(7): 537-61.
  10. Drobna M, Szarzynska-Zawadzka B, Dawidowska M. T-cell acute lymphoblastic leukemia from miRNA perspective: Basic concepts, experimental approaches, and potential biomarkers. Blood Rev 2018; 32(6): 457-72.
  11. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2012; 26(1): 1-12.
  12. Li M, Fu W, Wo L, Shu X, Liu F, Li C. miR-128 and its target genes in tumorigenesis and metastasis. Exp Cell Res 2013; 319(20): 3059-64.
  13. Jin J, Wang Y, Xu Y, Zhou X, Liu Y, Li X, et al. MicroRNA-144 regulates cancer cell proliferation and cell-cycle transition in acute lymphoblastic leukemia through the interaction of FMN2. J Gene Med 2017; 19(6-7): e2898.
  14. Rasmussen KD, Simmini S, Abreu-Goodger C, Bartonicek N, Di GM, Bilbao-Cortes D, et al. The miR-144/451 locus is required for erythroid homeostasis. J Exp Med 2010; 207(7): 1351-8.
  15. Pan X, Wang R, Wang ZX. The potential role of miR-451 in cancer diagnosis, prognosis, and therapy. Mol Cancer Ther 2013; 12(7): 1153-62.
  16. Lu F, Zhang J, Ji M, Li P, Du Y, Wang H, et al. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol 2014; 45(1): 383-92.
  17. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011; 118(11): 3072-9.
  18. Nemes K, Csoka M, Nagy N, Mark A, Varadi Z, Danko T, et al. Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia. Pathol Oncol Res 2015; 21(3): 597-604.
  19. Rzepiel A, Kutszegi N, Gezsi A, Sagi JC, Egyed B, Peter G, et al. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia. J Transl Med 2019; 17(1): 372.
  20. Kutszegi N, Rzepiel A, Gezsi A, Papp M, Egyed B; et al. Monitoring the potential role of circulating miR-181b-5p in minimal residual disease in pediatric acute lymphoblastic leukaemia. J Extracell Vesicles 2018; 7(Suppl 1): 241.
Journal of Isfahan Medical School
Volume 38, Issue 603 - Serial Number 603
November and December 2021
Pages 914-920

Files

History

  • Receive Date: 11 June 2020
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics